Angarano G, Carbonara D, Costa D
New Microbiol. 1995 Jan;18(1):69-72.
A multicentric prospective study started in March '93 to describe both initial and acquired resistance of Mycobacterium Tuberculosis in Italian HIV+ patients (pts.) to first line drugs: Rifampin (R), Isoniazid (I), Pyrazinamide (P), Ethambutol (E), Streptomycin (S). All tuberculosis (TB) cases diagnosed in HIV+ patients (pts.) were included, along with clinical-anamnestical data. Drug-susceptibility tests were performed centrally. Preliminary results indicate an overall low frequency of TB resistance to first line drugs: R = 2%, P = 4%, S = 9%, I/E = none. However, a relevant nosocomial outbreak of multiple drug resistant (DR) TB was detected. This finding, along with some previous Italian reports of DR-TB clusters, may herald a further spread of DR-TB. Surveillance, therefore, is mandatory in Italy from now on.
一项多中心前瞻性研究于1993年3月启动，旨在描述意大利HIV阳性患者中结核分枝杆菌对一线药物（利福平（R）、异烟肼（I）、吡嗪酰胺（P）、乙胺丁醇（E）、链霉素（S））的初始耐药性和获得性耐药性。纳入了所有在HIV阳性患者中诊断出的结核病（TB）病例以及临床病史数据。药敏试验在中心实验室进行。初步结果表明，结核病对一线药物的总体耐药频率较低：利福平耐药率为2%，吡嗪酰胺为4%，链霉素为9%，异烟肼/乙胺丁醇无耐药。然而，检测到一起相关的耐多药（DR）结核病医院内暴发。这一发现，连同意大利之前一些关于耐多药结核病聚集性病例的报告，可能预示着耐多药结核病的进一步传播。因此，从现在起在意大利进行监测是必不可少的。
